Matching articles for "PPSV23"
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734f
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734g
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Issue 1713 · October 14, 2024 Free
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine

The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):161-3 doi:10.58347/tml.2024.1713a
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
Issue 1713 · October 14, 2024 Free
Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)

View Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e163 doi:10.58347/tml.2024.1713f
View Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old
Issue 1713 · October 14, 2024 Free
Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)

View Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e164 doi:10.58347/tml.2024.1713g
View Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old
Issue 1710 · September 2, 2024
Drugs for COPD

The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD…

Med Lett Drugs Ther. 2024 Sep 2; 66(1710):137-44 doi:10.58347/tml.2024.1710a
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Issue 1661 · October 17, 2022
Adult Immunization

The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these…

Med Lett Drugs Ther. 2022 Oct 17; 64(1661):161-8
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Issue 1661 · October 17, 2022 Free
Expanded Table: Some Vaccines for Adults (online only)
Med Lett Drugs Ther. 2022 Oct 17; 64(1661):e170-3
Issue 1638 · November 29, 2021
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of…

Med Lett Drugs Ther. 2021 Nov 29; 63(1638):188-90
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old.
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1546 · May 7, 2018
Adult Immunization

The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with…

Med Lett Drugs Ther. 2018 May 7; 60(1546):73-82
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
Issue 1546 · May 7, 2018
Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

View the Expanded Table: Some Vaccines Recommended for Use in Adults

Med Lett Drugs Ther. 2018 May 7; 60(1546):e82-5
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Issue 1479 · October 12, 2015 Free
Addendum: PCV13 for Adults 65 Years and Older

In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal…

Med Lett Drugs Ther. 2015 Oct 12; 57(1479):144
In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal conjugate vaccine (PCV13) followed 6 to 12 months later by the pneumococcal polysaccharide vaccine (PPSV23) (Med Lett Drugs Ther 2014; 56:102) . In June 2015, the ACIP changed the recommended interval between the two vaccines to >1 year for immunocompetent adults ≥65 years old (MMWR Morbid Mortal Wkly Rep 2015; 674:944). Separating the vaccines by a year or more may improve the immune response to the serotypes in both vaccines. If a dose of PPSV23 is given earlier than the recommended interval, it does not need to be repeated. Download complete U.S. English article
Issue 1453 · October 13, 2014 Free
In Brief: PCV13 for Adults 65 Years and Older

The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), in addition to the 23-valent pneumococcal…

Med Lett Drugs Ther. 2014 Oct 13; 56(1453):102
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23 ), for all adults ≥65 years old. 1 An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo. 2 Adults ≥65 years old who previously received ≥1 dose of PPSV23 should also receive PCV13, but at least one year after the last dose of PPSV23. For those receiving the pneumococcal vaccine for the first time, PCV13 should be given first, followed 6-12 months later by PPSV23. PCV13 can be given at the same time as an inactivated influenza vaccine. Currently, Medicare only pays for one lifetime dose of a pneumococcal vaccine for healthy patients. S Tomczyk et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822. M Bonten et al. Community acquired pneumonia immunisation trial in adults (CAPITA). Abstract #O-015. International Symposium on Pneumococci and Pneumococcal Diseases 2014. Available at: http://isppd.meetingxpert.net. Accessed October 2, 2014. Download complete U.S. English article
Issue 112 · December 1, 2011
Adult Immunizations

Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.

Treat Guidel Med Lett. 2011 Dec; 9(112):75-82
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Issue 1314 · June 15, 2009 Free
Pneumococcal Vaccination of Adults: Polysaccharide or Conjugate?

A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):47-8
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic pneumonia), but not mortality, in immunocompetent older adults.2 PPSV23 has not been shown to reduce the risk of invasive pneumococcal disease (IPD) in immunocompromised patients. Click here to view the free full article.
Issue 80 · April 1, 2009
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2009 Apr; 7(80):27-36
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.